LYOPHILIZED PHARMACEUTICAL COMPOSITIONS FOR VAGINAL DELIVERY
First Claim
Patent Images
1. A solid lyophilized vaginal dosage form including:
- a) an effective amount of at least one active ingredient;
b) a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form; and
c) at least one polymeric mucoadhesive matrix forming agent;
wherein the dosage form has a pH of about 4.0 to 5.0, and disintegrates within 120 seconds after being contacted with a vaginal mucosa.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein is a solid lyophilized vaginal dosage form that can have an effective amount of at least one active ingredient, a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form, and at least one polymeric mucoadhesive matrix forming agent. The dosage form can have a pH of about 4.0 to 5.0, and can disintegrate within 120 seconds after being contacted with a vaginal mucosa. A method of delivering an active ingredient to the vaginal mucosa using the disclosed solid dosage form is also described.
3 Citations
21 Claims
-
1. A solid lyophilized vaginal dosage form including:
-
a) an effective amount of at least one active ingredient; b) a crystalline structure forming agent in an amount of about 5 wt. % to about 40 wt. %, based on the total weight of the lyophilized dosage form; and c) at least one polymeric mucoadhesive matrix forming agent; wherein the dosage form has a pH of about 4.0 to 5.0, and disintegrates within 120 seconds after being contacted with a vaginal mucosa. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)
-
Specification